PMID- 29434819
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 15
IP  - 2
DP  - 2018 Feb
TI  - Tangshen formula improves inflammation in renal tissue of diabetic nephropathy 
      through SIRT1/NF-kappaB pathway.
PG  - 2156-2164
LID - 10.3892/etm.2017.5621 [doi]
AB  - The present study investigated the mechanism underlying the anti-inflammatory 
      effects of Tangshen formula (TS) in Sprague Dawley (SD) rats with diabetic 
      nephropathy (DN). A rat model of DN was established by intraperitoneal injection 
      of 1% (40 mg/kg) streptozotocin and administration of a high fat and glucose 
      diet. Subsequently, SD rats were randomly divided into six groups (n=8): A DN 
      group, a valsartan group, a high-dose TS group, a middle-dose TS group, a 
      low-dose TS group and a control group with normal SD rats. Once rats received 
      their allocated treatment for 12 weeks, body weight and kidney weight were 
      recorded, and fasting blood glucose, ratio of urinary protein, beta(2)-MG and 
      creatinine clearance rate were determined. Furthermore, hemodynamic indices, 
      including plasma viscosity and whole blood reduction viscosity were detected. 
      Immunohistochemistry was used to detect the infiltration of macrophages in the 
      kidneys of rats. Reverse transcription-quantitative polymerase chain reaction and 
      western blotting were performed to investigate the activation; mRNA and protein 
      expression levels of monocyte chemoattractant protein-1 (MCP-1), macrophage 
      migration inhibitory factor (MIF), nuclear factor-kappaB (NF-kappaB) and sirtuin-1 
      (SIRT1) in each group. In comparison with the DN group, each biochemical 
      indicator of rats in the high-dose TS group was significantly decreased (P<0.05). 
      Blood viscosity in each treatment group was significantly decreased when compared 
      with the DN group (P<0.01). Hematoxylin and eosin staining indicated that the 
      infiltration of macrophages was significantly decreased in the high-dose TS group 
      when compared with the DN group (P<0.01). mRNA and protein expression levels of 
      MCP-1 and MIF in the high-dose TS group were significantly decreased when 
      compared with the DN group (P<0.05). In the treatment groups, SITR1 mRNA 
      expression levels were significantly increased, whereas the mRNA expression 
      levels of NF-kappaB were significantly decreased (P<0.01). Western blotting results 
      indicated a significant decrease in the protein expression levels of acetylated 
      NF-kappaB in the treatment groups when compared with the DN group (P<0.01) and the 
      propensity of protein expression of the other inflammatory factors were 
      consistent with the mRNA findings. The results of the high-dose TS group were 
      similar to those of the valsartan group. The present study indicates that TS was 
      able to activate SITR1, which lead to NF-kappaB deacetylation, thus reducing the 
      release of inflammatory factors and decreasing the severity of diabetic 
      nephropathy.
FAU - Du, Yue-Guang
AU  - Du YG
AD  - Department of Pathology, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 
      310053, P.R. China.
FAU - Zhang, Ke-Na
AU  - Zhang KN
AD  - Department of Pathology, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 
      310053, P.R. China.
FAU - Gao, Zong-Lei
AU  - Gao ZL
AD  - National Traditional Chinese Medicine Clinical Research Center, Zhejiang Chinese 
      Medical University, Hangzhou, Zhejiang 310053, P.R. China.
FAU - Dai, Fengjiao
AU  - Dai F
AD  - National Traditional Chinese Medicine Clinical Research Center, Zhejiang Chinese 
      Medical University, Hangzhou, Zhejiang 310053, P.R. China.
FAU - Wu, Xi-Xi
AU  - Wu XX
AD  - National Traditional Chinese Medicine Clinical Research Center, Zhejiang Chinese 
      Medical University, Hangzhou, Zhejiang 310053, P.R. China.
FAU - Chai, Ke-Fu
AU  - Chai KF
AD  - National Traditional Chinese Medicine Clinical Research Center, Zhejiang Chinese 
      Medical University, Hangzhou, Zhejiang 310053, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20171212
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC5776509
OTO - NOTNLM
OT  - Tangshen formula
OT  - diabetic nephropathy
OT  - macrophages
OT  - nuclear factor-kappaB
OT  - sirtuin
EDAT- 2018/02/13 06:00
MHDA- 2018/02/13 06:01
PMCR- 2017/12/12
CRDT- 2018/02/14 06:00
PHST- 2016/01/20 00:00 [received]
PHST- 2017/02/24 00:00 [accepted]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/13 06:00 [pubmed]
PHST- 2018/02/13 06:01 [medline]
PHST- 2017/12/12 00:00 [pmc-release]
AID - ETM-0-0-5621 [pii]
AID - 10.3892/etm.2017.5621 [doi]
PST - ppublish
SO  - Exp Ther Med. 2018 Feb;15(2):2156-2164. doi: 10.3892/etm.2017.5621. Epub 2017 Dec 
      12.